| Literature DB >> 32416867 |
Francis S Willard1, Joseph D Ho2, Kyle W Sloop3.
Abstract
The glucagon-like peptide-1 receptor (GLP-1R) is a significant therapeutic target for small molecule drug discovery given the therapeutic impact of peptide agonists in the diabetes sphere. We review the discovery and subsequent characterization of the small molecule GLP-1R allosteric modulator 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP). BETP is a covalent modulator of the GLP-1R, and we discuss the pharmacological implications and possible structural basis of this novel mode of action. We highlight the insights into class B G-protein coupled receptor pharmacology and biology provided by studies conducted with BETP. These include the descriptions of exquisite allosteric modulator probe dependence and biased signaling in vitro and in vivo. We conclude with an analysis of the utility of BETP as a chemical probe for the GLP-1R.Entities:
Keywords: Agonist; Allosteric modulator; BETP; Class B GPCR; Covalent; Drug discovery; G-protein coupled receptor; Glucagon-like peptide 1; Insulin; Transmembrane helix
Year: 2020 PMID: 32416867 DOI: 10.1016/bs.apha.2020.02.001
Source DB: PubMed Journal: Adv Pharmacol ISSN: 1054-3589